Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 38
Selected: 0
NCT IDTitle
NCT02160626Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
NCT05791474ATI-2231 in Advanced Solid Tumor Malignancies
NCT01986920Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
NCT03594227ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
NCT05114889Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
NCT03148691A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
NCT03315689Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT05432596Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT03585296A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
NCT03468855A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
NCT02260180Study of A-101 for the Treatment of Seborrheic Keratosis
NCT03380390Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT02669862A Study of A-101 Solution in Subjects With Common Warts.
NCT03691831A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT04598269Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
NCT04524858Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
NCT05216224ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06648434MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT03495817A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
NCT03551821Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
NCT06585202Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03812510Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT07011706ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT03278028A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT05511519Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
NCT02667236A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
NCT05279417ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
NCT03210337A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03354637A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
NCT04247815Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
NCT03487588An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
NCT02667275A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
NCT06374459Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT03759340ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03687372Study of A-101 Topical Solution for the Treatment of Common Warts
NCT02667288An Open-Label Safety Study of A-101 Solution
NCT03224598A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
NCT05932654POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis